News

Article

Beckman Coulter Life Sciences and IncellDx Announce Collaboration

Beckman Coulter Life Sciences and IncellDx have announced a collaboration aimed at creating awareness for the oncology assays on the cytometry platform for European customers.

Beckman Coulter Life Sciences and IncellDx have announced, in a Nov. 20, 2019 press release, a collaboration aimed at creating awareness for the oncology assays on the cytometry platform for European customers.

Four cancer detection reagents were developed by IncellDx using Beckman Coulter’s instruments, under the partnership. The assays relate to lung and bladder cancers as well as human papillomavirus (HPV) cancers affecting the head, neck, and cervix.

“The new partnership brings the power of multi-parameter flow cytometry to molecular testing, improving workflow while delivering sensitive and highly reliable cell identification,” said Mario Koksch, vice-president and general manager, Beckman Coulter Life Sciences Cytometry Business Unit, in the press release. “In addition, the oncology menu of IncellDx adds a new dimension to Beckman Coulter instruments, such as the CytoFLEX Series, which positions our technology at the forefront of clinical research.”

Bruce Patterson, CEO and founder of IncellDx, commented, “In cancer research, it is essential to carry out quantification at the single cell level. Adding our single cell, simultaneous protein, mRNA, and cell cycle/DNA content assays to the technology behind Beckman Coulter Life Sciences flow cytometry instruments will open up a new era in understanding cancer biology.”

Source: Beckman Coulter

 

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content